Acquired Orphan Blood Diseases Therapeutics Market by Product Type, Distribution Channel, End User 2024-2032

1
Global Acquired Orphan Blood Diseases
Therapeutics Market Research and Forecast Report
2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Acquired Orphan Blood Diseases
  Therapeutics Market Global Industry Trends,
  Share, Size, Growth, Opportunity and Forecast
  2024-2032," the global acquired orphan blood
  diseases therapeutics market size reached US 8.8
  Billion in 2023.
• Acquired orphan blood disease therapeutics refers
  to the specialized medical treatments designed
  for rare blood disorders that are developed
  post-birth. They include a range of treatment
  modalities, such as targeted therapies,
  biologics, small molecule inhibitors, and gene
  therapies. Acquired orphan blood disease
  therapeutics are engineered to combat specific
  aspects of the disorder by utilizing complex
  biological components, proteins, or synthetic
  molecules. They are employed in hospitals,
  specialized treatment centers, and research
  institutions.
• Acquired orphan blood disease therapeutics offer
  numerous benefits, including early intervention,
  personalized treatment plans, improved patient
  quality of life, minimized disease progression,
  and curative possibilities. Additionally, they
  offer reduced side effects, targeted drug
  delivery, quicker recovery, cost-effectiveness in
  long-term disease management, and an increased
  treatment success rate.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/acquired-orphan-blood-d
  iseases-therapeutics-market/requestsample

4
Report Description

• Global Acquired Orphan Blood Diseases
  Therapeutics Market Trends
• The rapid advancements in medical research
  contributing to the identification and
  development of effective and targeted treatments
  for acquired orphan blood diseases, are major
  factors propelling the market growth. Moreover,
  the implementation of government policies and
  incentives, such as exclusive marketing rights
  and tax credits that encourage pharmaceutical
  companies to invest in research and innovation
  initiatives, is supporting the market growth.
  Along with this, the growing awareness and
  advocacy efforts by patient organizations and
  healthcare providers to educate the public and
  policy-makers about the critical need for
  treatment is stimulating the market growth.
  Besides this, rapid advances in genomic and
  proteomic technologies leading to the precise
  identification of disease etiologies are
  anticipated to drive the market growth.
  Furthermore, the rising partnerships and
  collaborations among research institutions,
  pharmaceutical companies, and healthcare
  providers for sharing knowledge, resources, and
  financial risks that accelerate the development
  and distribution of therapeutics are bolstering
  the market growth. In addition to this, the
  increasing establishment of specialized
  healthcare facilities and the availability of
  skilled professionals that serve to decentralize
  treatment, making it more accessible to a broader
  patient base, is acting as a growth-inducing
  factor. Apart from this, the rising prevalence of
  personalized medicine and the growing focus on
  patient-centric care models are also favoring the
  market growth. In line with this, the sudden
  shift towards value-based healthcare that impacts
  reimbursement policies, making it financially
  viable for healthcare providers and patients to
  opt for advanced treatment options, is creating
  remunerative growth opportunities for the market.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/acquired-orphan-blood-d
  iseases-therapeutics-market

5
Report Segmentation

• Therapy Insights
• Recombinant Factor
• Immunoglobulin Infusion Therapy
• Activated Prothrombin Complex Concentrate
• Thrombopoietin Receptor Agonists
• Others
• Disease Indication Insights
• Acquired Agranulocytosis
• Acquired Hemophilia
• Acquired Von Willebrand Syndrome
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Myelodysplastic Syndrome
• Others

6
Report Segmentation

• Distribution Channel Insights
• Hospital Pharmacy
• Retail Pharmacy
• Others
• Regional Insights
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7
Competitive Landscape with Key Players

• Alexion Pharmaceuticals Inc. (AstraZeneca plc)
• Amgen Inc.
• GSK plc
• Novartis AG
• Novo Nordisk A/S
• Otsuka Pharmaceutical Co. Ltd.
• Rigel Pharmaceuticals Inc.
• Roche Holding AG
• Sanofi
• Takeda Pharmaceutical Company Limited

8
Key Questions Answered in the Report
9
Key Questions Answered in the Report
10
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Acquired Orphan Blood
  Diseases Therapeutics Market    5.1    Market
  Overview    5.2    Market Performance    5.3  
   Impact of COVID-19  5.4    Market Forecast
• 6     Market Breakup by Therapy    6.1  
   Recombinant Factor        6.1.1 Market Trends 
        6.1.2 Market Forecast    6.2  
   Immunoglobulin Infusion Therapy        6.2.1
  Market Trends        6.2.2 Market Forecast   
  6.3    Activated Prothrombin Complex
  Concentrate        6.3.1 Market Trends       
  6.3.2 Market Forecast       

11
Table of Contents

•     6.4    Thrombopoietin Receptor Agonists     
    6.4.1 Market Trends        6.4.2 Market
  Forecast    6.5    Others        6.5.1 Market
  Trends        6.5.2 Market Forecast7   Market
  Breakup by Disease Indication    7.1    Acquired
  Agranulocytosis        7.1.1 Market Trends     
    7.1.2 Market Forecast    7.2    Acquired
  Hemophilia        7.2.1 Market Trends       
  7.2.2 Market Forecast    7.3    Acquired Von
  Willebrand Syndrome        7.3.1 Market Trends 
        7.3.2 Market Forecast    7.4    Paroxysmal
  Nocturnal Hemoglobinuria (PNH)        7.4.1
  Market Trends        7.4.2 Market Forecast   
  7.5    Myelodysplastic Syndrome        7.5.1
  Market Trends        7.5.2 Market Forecast   
  7.6    Others        7.6.1 Market Trends       
  7.6.2 Market Forecast8   Market Breakup by
  Distribution Channel    8.1    Hospital
  Pharmacy        8.1.1 Market Trends       
  8.1.2 Market Forecast
• For more information, visit https//www.imarcgrou
  p.com/acquired-orphan-blood-diseases-therapeutics-
  market/toc

12
Disclaimer

• 2023 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

13
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE [phone] E-MAIL
sales_at_imarcgroup.com